October 25, 2001 — BASKING RIDGE, NJ — With its recent acquisition of a North Carolina manufacturing facility, Cardinal Health said it plans to increase production of its biotech and pharmaceutical products.

Financial terms of the deal were not disclosed.

The 75,000 square foot plant, which had been used by Schering-Plough Corp, is located in Raleigh. Company officials say the plant will double Cardinal’s capacity to contract and manufacture its drugs.

“The location of the new facility is really ideal,” said Frank Leo, president of the Sterile Technologies unit of Cardinal’s Pharmaceutical Technologies and Services group. “Our New Mexico operations will serve the needs of the many drug developers on the West Coast, allowing us to focus the production in Raleigh on serving drug companies in the Northeast.”

Up to 35 workers are expected to employed at the plant in the coming year, and up to 70 in two two years. Cardinal currently employs more than 8,400 people worldwide at 33 drug development, manufacturing and packaging centers in 11 countries.